945771-74-4

Usage

Uses

Used in Oncology:
BNC105 is used as an anticancer agent for its ability to target and destroy the blood supply of tumors, leading to cell death. It has demonstrated effectiveness in preclinical studies for a variety of solid tumors, such as breast, lung, ovarian, and colon cancer.
Used in Enhancing Anticancer Agent Activity:
BNC105 is used to enhance the activity of other anticancer agents, potentially improving the overall efficacy of cancer treatment. It is currently being investigated in clinical trials for the treatment of solid tumors, with its unique mechanism of action and promising preclinical and clinical data suggesting its potential as a therapy for a range of tumor types.

Upstream product

• 905752-30-9 7-O-acyl-2-bromo-6-methoxy-3-(3,4,5-trimethoxybenzoyl)-benzo[b]furan 
• 917-54-4 methyllithium 
• 25245-29-8 5-iodo-1,2,3-trimethoxybenzene 
• 905752-32-1 2-t-butyldimethylsilyl-3-formyl-6-methoxy-7-isopropoxybenzofuran 
• 905752-33-2 2-t-butyldimethylsilyl-7-isopropoxy-6-methoxy-3-(3,4,5-trimethoxybenzoyl)-benzo[b]furan 
• 1007198-30-2 C₂₅H₃₂O₇Si 
• 905752-39-8 7-O-acyl-2-(t-butyldimethylsilyl)-6-methoxy-3-(3,4,5-trimethoxybenzoyl)-benzo[b]furan 
• 18815-74-2 zinc methyl bromide 
• 945772-22-5 3-(t-butyldimethylsilyl)-1-(3,4,5-trimethoxyphenyl)propynone 
• 1211292-80-6 1-(3,4,5-trimethoxyphenyl)but-2-yn-1-ol 
• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 905752-38-7 2-(t-butyldimethylsilyloxy)-7-isopropoxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxy-benzofuran 
• 905752-37-6 2-(tert-butyldimethylsilyloxy)-7-acetoxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran 
• 103275-75-8 2-isopropoxy-3-methoxyphenol 

Downstream Products

• 945772-29-2 2-methyl-3-(3,4,5-trimethoxybenzoyl)-6-methoxy-7-O-acyl-benzo[b]furan 
• 945828-45-5 dibenzyl 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate 
• 945772-45-2 C₂₀H₂₁O₁₀P 

Relevant academic research and scientific papers

METHOD FOR TREATING ACUTE MYELOID LEUKEMIA

The present invention relates to a method for the treatment of acute myeloid leukemia (AML) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of the presently-described formula (I) or a salt,

Combination Therapy for Treating Proliferative Diseases

The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.

COMBINATION TREATMENT PROTOCOL

The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).

A THERAPEUTIC PROTOCOL FOR TREATING OVARIAN CANCER

The present invention is directed to a pharmaceutical combination for treating proliferative disease comprising a compound of formula (I), or a salt, solvate or prodrug thereof, carboplatin or cisplatin, and gemcitabine. The present invention is further d

A synthetic BNC105 method

The invention relates to a method for compounding BNC 105, which uses o-vanillin and 3,4,5- trimethoxy-benzaldehyde as starting materials. The o-vanillin is subjected to hydroxy protection and aldehyde oxidation to be hydrolyzed into phenol, and the pheno

METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA

The present disclosure provides methods for treating chronic lymphocytic leukemia (CLL) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of formula (I) or a salt, solvate or prodrug thereof.

COMBINATION THERAPY INVOLVING A VASCULAR DISRUPTING AGENT AND AN AGENT WHICH TARGETS HYPOXIA

The present invention provides a method for treating a proliferative disease in a patient. The method comprises administering to a patient in need thereof: a) a vascular disrupting agent and (b) at least one hypoxia targeting agent. Preferred combinations

CHEMICAL PROCESSES FOR THE MANUFACTURE OF SUBSTITUTED BENZOFURANS

The present invention relates to the scaled-up synthesis of biologically active compounds which display useful therapeutic activity in treating proliferative disorders. In particular the invention relates to process methods for the kilogram scale synthesi

Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[ b ]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties

A structure-activity relationship (SAR) guided design of novel tubulin polymerization inhibitors has resulted in a series of benzo[b]furans with exceptional potency toward cancer cells and activated endothelial cells. The potency of early lead compounds has been substantially improved through the synergistic effect of introducing a conformational bias and additional hydrogen bond donor to the pharmacophore. Screening of a focused library of potent tubulin polymerization inhibitors for selectivity against cancer cells and activated endothelial cells over quiescent endothelial cells has afforded 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105, 8) as a potent and selective antiproliferative. Because of poor solubility, 8 is administered as its disodium phosphate ester prodrug 9 (BNC105P), which is rapidly cleaved in vivo to return the active 8. 9 exhibits both superior vascular disrupting and tumor growth inhibitory properties compared with the benchmark agent combretastatin A-4 disodium phosphate 5 (CA4P).

TREATMENT OF MACULAR DEGENERATION

The present invention relates generally to methods for treating macular degeneration, and in particular age-related macular degeneration, involving the use of specific benzofuran based compounds.